Karyopharm Therapeutics
Nicholas Park is an accomplished accounting professional currently serving as the Director of Accounting and Reporting at Karyopharm Therapeutics Inc. since May 2022. Prior to this role, Nicholas held various positions at Alnylam Pharmaceuticals, including Associate Director and Senior Manager of Corporate Accounting, and served as Consolidations Manager at Shire. Nicholas has extensive experience managing teams and overseeing complex accounting functions, including purchase price allocations and revenue recognition, particularly during tenure at Five Star Senior Living. Early career experience includes positions at Ernst & Young and Marcum LLP in audit practices, as well as a foundation in accounting from roles at Murphy Edwards Goncalves & Ferrera, PC and in the United States Air Force. Nicholas holds an MBA from Boston College and a Bachelor’s degree in Business Administration from Framingham State University.
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).